Pharmacodynamic interaction between pantoprazole and vecuronium at neuromuscular junction.
Summary of "Pharmacodynamic interaction between pantoprazole and vecuronium at neuromuscular junction."
1â€‚The effect of pantoprazole on vecuronium-induced neuromuscular blockade in in vivo has not been clearly defined. In this study, we demonstrate that chronic administration, but not acute administration, of pantoprazole alters the pattern of vecuronium-induced neuromuscular blockade. 2â€‚This study was designed to evaluate the effect of acute and chronic administration of pantoprazole on vecuronium-induced neuromuscular blockade using the rat in vivo sciatic nerve-stimulated gastrocnemius preparation. 3â€‚Vecuronium was administered as a slow intravenous infusion (29.41â€ƒÎ¼gâ€ƒkg(-1) â€ƒmin(-1) ) until the gastrocnemius twitch response to sciatic nerve stimulation was completely abolished. The effect of acute (single dose, i.v.) and chronic administration (per oral for 21â€ƒdays) of pantoprazole (3.64â€ƒmgâ€ƒkg(-1) ) on vecuronium-induced blockade was assessed by comparing ED(50) values, time required for 50% block, ED(95) values, block duration and percentage of recovery with respect to control. 4â€‚Acute administration of pantoprazole had no significant effect on any parameter of vecuronium-induced neuromuscular blockade. Chronic administration of pantoprazole significantly reduced vecuronium ED(50) value, time for 50% block, ED(95) value and percentage recovery from blockade compared with the control group (Pâ€ƒ<â€ƒ0.05). Reduction in the duration of vecuronium-induced blockade was not significantly affected by chronic treatment with pantoprazole compared with control. 5â€‚On chronic administration, pantoprazole may produce earlier block, quick relaxation and reduces the recovery of vecuronium without affecting its duration of action.
Department of Pharmacology, Government Medical College, Bhavnagar 364001, Gujarat, India.
This article was published in the following journal.
Name: Autonomic & autacoid pharmacology
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/21342416
- DOI: http://dx.doi.org/10.1111/j.1474-8673.2011.00463.x
Medical and Biotech [MESH] Definitions
Neuromuscular Junction Diseases
Conditions characterized by impaired transmission of impulses at the NEUROMUSCULAR JUNCTION. This may result from disorders that affect receptor function, pre- or postsynaptic membrane function, or ACETYLCHOLINESTERASE activity. The majority of diseases in this category are associated with autoimmune, toxic, or inherited conditions.
Neuromuscular Blocking Agents
Drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. They can be of two types, competitive, stabilizing blockers (NEUROMUSCULAR NONDEPOLARIZING AGENTS) or noncompetitive, depolarizing agents (NEUROMUSCULAR DEPOLARIZING AGENTS). Both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.
Signs and symptoms associated with diseases of the muscle, neuromuscular junction, or peripheral nerves.
The intentional interruption of transmission at the NEUROMUSCULAR JUNCTION by external agents, usually neuromuscular blocking agents. It is distinguished from NERVE BLOCK in which nerve conduction (NEURAL CONDUCTION) is interrupted rather than neuromuscular transmission. Neuromuscular blockade is commonly used to produce MUSCLE RELAXATION as an adjunct to anesthesia during surgery and other medical procedures. It is also often used as an experimental manipulation in basic research. It is not strictly speaking anesthesia but is grouped here with anesthetic techniques. The failure of neuromuscular transmission as a result of pathological processes is not included here.
Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.
PURPOSE: To assess the degree of neuromuscular block acceleromyographically at the sternocleidomastoid muscle. METHODS: Eighteen adult patients scheduled for air-oxygen-sevoflurane-fentanyl and epidur...
Objectiveâ€‚ To evaluate the potency and duration of three subparalyzing doses of vecuronium (VEC) in isoflurane-anesthetized horses. Study designâ€‚ Prospective experimental study. Animalsâ€‚ Thirtee...
ABSTRACT: BACKGROUND: Acetylcholinesterase inhibitors cannot rapidly reverse profound neuromuscular block. Sugammadex, a selective relaxant binding agent, reverses the effects of rocuronium and vecuro...
Objectiveâ€‚ To compare the duration of action of vecuronium in diabetic dogs with a control group. Study designâ€‚ Prospective clinical study. Animalsâ€‚ Forty client-owned diabetic (nâ€ƒ=â€ƒ20) and...
INTRODUCTION This article describes a method for spaced stimulation of Drosophila motor neurons. The neurons can be stimulated for short periods of time (~2 h) and then fixed (or imaged live). The met...
This study was conducted to determine and compare the safety and effectiveness of two neuromuscular blockers (rocuronium and vecuronium) at various doses in adults who are undergoing gener...
The purpose of the study is to assess the effects, if any, pantoprazole (proton pump inhibitor) has on absorption, distribution, metabolization and excretion of cladribine in the body. Cla...
The purpose of this study was to demonstrate in adult patients faster recovery from a neuromuscular block induced by either rocuronium or vecuronium after reversal at reappearance of T2 by...
The purpose of this study is to demonstrate pharmacodynamic comparability between the pantoprazole spheroid formulation and the marketed tablet formulation.
Primary objective: - Assess the effects of clopidogrel (300 mg loading dose followed by 4 days 75 mg/day) on Adenosine diphosphate (ADP)-induced platelet aggregation when given co...